Doxazosin in a gastrointestinal therapeutic system formulation

Area of Science:

• Pharmacology and Drug Delivery
• Cardiovascular Medicine
• Urology

Background:

• Doxazosin is a widely used medication for hypertension and benign prostatic hypertrophy.
• Standard doxazosin formulations require dose titration to manage side effects and optimize efficacy.
• Variability in drug absorption can lead to suboptimal therapeutic outcomes.

Purpose of the Study:

• To introduce and evaluate a novel gastrointestinal therapeutic system (GITS) formulation of doxazosin.
• To assess the pharmacokinetic profile and clinical efficacy of doxazosin GITS compared to standard formulations.
• To determine if doxazosin GITS reduces the need for dose titration and improves patient tolerance.

Main Methods:

• Development of a new doxazosin formulation utilizing gastrointestinal therapeutic system (GITS) technology.
• Pharmacokinetic studies to analyze drug absorption rates and plasma concentration profiles.
• Clinical trials in patients with hypertension and symptomatic benign prostatic hypertrophy to assess efficacy and tolerability.

Main Results:

• The doxazosin GITS formulation demonstrated a more gradual absorption profile.
• A reduced plasma doxazosin trough-to-peak ratio was observed with the GITS formulation.
• Doxazosin GITS showed comparable efficacy to the standard formulation but with significantly better tolerance and no requirement for titration.

Conclusions:

• Doxazosin GITS represents an advancement in drug delivery for hypertension and benign prostatic hypertrophy.
• The GITS formulation offers improved pharmacokinetic control, leading to better patient tolerance and simplified treatment regimens.
• This new formulation eliminates the need for dose titration, potentially enhancing patient adherence and long-term management.